Tech Company Financing Transactions
DNA Script Funding Round
On 1/6/2022, DNA Script raised $200 million in Series C funding from Baillie Gifford, Casdin Capital and Catalio Capital Management.
Transaction Overview
Company Name
Announced On
1/6/2022
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script's first commercial product powered by its proprietary EDS technology.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
650 Gateway Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Donald Kania
Chief Executive Officer
Thomas Ybert
Chief Operating Officer
Sylvain Gariel
Browse more venture capital transactions:
Prev: 1/6/2022: Focal Systems venture capital transaction
Next: 1/6/2022: Erbi Biosystems venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs